Search the Newsreel

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VSTM) 2026-08-07

Erasca Shareholder Alert: ClaimsFiler Reminds Investors

ClaimsFiler is reminding investors in Erasca, Inc. (NasdaqGS: ERAS) that they have until August 10, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the preclinical data …

Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...

Verastem Inc (VSTM) reported strong Q2 2026 net product revenues of $25.1 million, reflecting a significant rebound due to improved commercial execution for its LGSOC franchise. The company also secured a non-dilutive royalty financing agreement of up to $75 million, strengthening its balance sheet …

ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Erasca, Inc. (NASDAQ:ERAS) on behalf of investors who purchased securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca made misleading statements regarding ERAS-0015's preclinical data, which was …

Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary

Verastem, Inc. reported its 2026 quarterly results, showing a significant increase in revenue to $40.08M from $2.14M in the prior year, primarily due to the commercial launch of AVMAPKI FAKZYNJA CO-PACK. The company also narrowed its net loss to ($34.67M) and improved diluted loss …

Verastem earnings beat by $0.12, revenue topped estimates

Verastem (NASDAQ: VSTM) reported strong second-quarter results, beating analyst EPS estimates by $0.12 with earnings of $-0.310 and significantly exceeding revenue forecasts at $40.07M against an estimated $23.09M. The company's stock has seen a 20.860% increase in the last three months and a 5.160% …

Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines - ERAS

Pomerantz LLP has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, urging investors with losses to come forward by the August 10, 2026, deadline. The lawsuit stems from two significant stock drops in April 2026. The first followed …

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) reported a Q2 loss of $0.35 per share, surpassing the Zacks Consensus Estimate of a $0.46 loss and exceeding prior year's loss of $0.39. The company's revenues for the quarter reached $40.08 million, significantly beating the Zacks Consensus Estimate by 73.12% and …

Kaplan Fox Urges Erasca, Inc. (NASDAQ: ERAS) Investors to Contact the Firm Before the Deadline on August 10, 2026

Kaplan Fox & Kilsheimer LLP is urging investors of Erasca, Inc. (NASDAQ: ERAS) to contact the firm by the August 10, 2026 deadline to serve as lead plaintiff in a class action lawsuit. The lawsuit alleges that Erasca made false and misleading statements regarding …

ERAS INVESTOR ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Hagens Berman is investigating potential securities law violations by Erasca, Inc. (NASDAQ: ERAS) following allegations that the company misled investors about its lead oncology candidate, ERAS-0015. The lawsuit claims Erasca provided a false narrative concerning the drug's competitive advantage, safety, and intellectual property, leading …

Erasca, Inc. Deadline: ERAS Investors with Losses in Excess of $100K Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit

Rosen Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) who purchased common stock between January 14, 2025, and April 26, 2026, about the August 10, 2026 deadline to serve as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Erasca …

Earnings Preview: Peraso to Report Financial Results Post-market on August 11

Peraso Inc. (NASDAQ: PRSO) is scheduled to release its financial results after the market closes on August 11, 2026. The company will also host a conference call and webcast to discuss these results on the same day at 5:00 p.m. ET. Investors and interested …

Peraso Inc (PRSO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Peraso Inc (PRSO) has an earnings forecast score of 9.00, ranking 1st in the Semiconductors & Semiconductor Equipment industry. Analysts have a strong buy rating for PRSO with an average price target of $2.73, suggesting a 212.35% upside. The company's next expected revenue is …

Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk

BlackRock, Inc. Trims Verastem Inc (VSTM) Stake in Recent 13DG Filing

BlackRock, Inc. has reduced its stake in Verastem Inc (VSTM) by 7,913 shares, a 0.13% decrease, as disclosed in a recent 13G filing. The biopharmaceutical company, specializing in anticancer agents, faces significant financial and operational challenges, reflected in its low GF-Score and weak profitability …

Verastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes

Verastem, Inc. CEO Dan Paterson sold 1,302 shares of common stock on August 3, 2026, at a price of $5.81 per share. This transaction was executed to fulfill statutory tax withholding requirements associated with the vesting of restricted stock units (RSUs) and was conducted …

Erasca earnings on deck: Can pipeline progress offset losses?

Erasca Inc. is set to report second-quarter results, with investor focus primarily on updates regarding its pan-RAS cancer drug, ERAS-0015, rather than expected financial losses. Despite being pre-revenue, analysts have a "Buy" rating on the stock with a significant price target, driven by promising …

The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch

This article highlights several low-priced growth stocks across diverse sectors—defense technology, biotechnology, digital media, and cross-border logistics—that are garnering investor attention due to recent significant business developments. Companies like Peraso Inc. (PRSO), Vistagen Therapeutics (VTGN), Ensysce Biosciences (ENSC), TNL Mediagene (TNMG), and Quanome Technologies …

Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announced an opportunity for Erasca, Inc. (ERAS) shareholders who suffered losses to lead a securities fraud class action lawsuit. The lawsuit alleges that between January 14, 2025, and April 26, 2026, Erasca made materially false and misleading …

VSTM|Verastem Inc|Price:5.695|Chg%:-0.105

Verastem Inc (VSTM) shows healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts currently rate the stock as a "Buy" with a target price indicating significant upside. …

The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS

The Gross Law Firm is reminding investors of Erasca, Inc. (ERAS) about a pending class action lawsuit. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges …

MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, and suffered substantial losses, …

Erasca (ERAS) to Post Earnings on Tuesday

ERAS 1-WEEK DEADLINE ALERT: HBSS Investigating Pending Claims Against Erasca (ERAS) in Securities Class Action Arising from Patent Litigation and Patient Safety Risks

Hagens Berman is investigating a securities class action against Erasca, Inc. (NASDAQ: ERAS) for alleged securities law violations. The lawsuit claims Erasca and its executives misled investors regarding its lead oncology candidate, ERAS-0015, by making false statements about its competitive advantage, safety profile, and …

DEADLINE ALERT for VIA, Z, ADMA, and ERAS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead …

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Erasca, Inc. (ERAS), Nano-X Imaging Ltd. (NNOX), and Black Rock Coffee Bar, Inc. (BRCB) Announced by Holzer & Holzer, LLC

ATLANTA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Erasca, Inc. (ERAS) The shareholder class action lawsuit filed against Erasca, Inc. (“Erasca”) (NASDAQ: ERAS) …

ERASCA DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

NEW YORK, Aug. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), of the important August …

A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18

This article provides an overview of current analyst ratings for Verastem (VSTM.US), highlighting a consensus price forecast ranging from $14 to $18. It serves as a quick snapshot of market sentiment and expectations for the company's stock performance.

Peraso Inc. Revenue Breakdown – NASDAQ:PRSO

Peraso Inc. (NASDAQ: PRSO) generated $12.19 million USD in revenue last year. The majority of this, $6.73 million USD, came from its MillimeterWave Integrated Circuits segment. Taiwan was the largest regional contributor, accounting for $5.28 million USD of the total revenue.

Vanguard Capital Management (VSTM) discloses 4.42M Verastem shares in 13G filing

Vanguard Capital Management LLC has filed a Schedule 13G, reporting a beneficial ownership of 4,423,544 shares of Verastem Inc (VSTM) common stock as of June 30, 2026. This represents a 5.03% stake in the company. Vanguard holds sole voting power over 572,036 shares and …

ERAS DEADLINE: The Gross Law Firm Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline

The Gross Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about an upcoming deadline for a securities class action lawsuit. Shareholders who purchased ERAS shares between January 14, 2025, and April 26, 2026, are encouraged to contact the firm regarding potential lead …

Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the ...

Robbins LLP is reminding investors of Erasca, Inc. (NASDAQ: ERAS) that a class action lawsuit has been filed against the company. The lawsuit alleges that Erasca failed to disclose that it was at risk of violating patent and trade secret protections and that its …

Peraso schedules an Aug. 11 call to discuss Q2 results

Peraso Inc. (NASDAQ: PRSO) will release its second-quarter 2026 financial results on Tuesday, August 11, 2026, after market close. A conference call will follow at 1:30 p.m. Pacific Time (4:30 p.m. Eastern) to discuss the results and business outlook. Investors can access the call …

Verastem, Inc. Revenue Breakdown – NASDAQ:VSTM

Verastem, Inc. (NASDAQ: VSTM) reported its revenue breakdown, with the Drugs segment being the top performer. The company generated $30.91 million USD last year, primarily from the United States, an increase from $10.00 million USD in the previous year.

Peraso to Announce Second Quarter 2026 Financial Results

Peraso Inc. announced it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after market close, followed by a conference call at 1:30 p.m. Pacific Time. The call will discuss the company's results and business outlook, with webcast and replay …